MiNK Therapeutics (NASDAQ:INKT) Stock Price Down 3.6% – Should You Sell?

MiNK Therapeutics, Inc. (NASDAQ:INKT) dropped 3.6% during mid-day trading on Friday . The stock traded as low as $11.04 and last traded at $11.05. 18,386 shares were traded during mid-day trading, an increase of 9% from the average daily volume of 16,857 shares. The stock had previously closed at $11.46.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on INKT shares. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of MiNK Therapeutics in a research note on Monday, May 18th. Weiss Ratings raised MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Finally, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

MiNK Therapeutics Trading Down 3.6%

The business has a fifty day moving average price of $11.52 and a two-hundred day moving average price of $11.41. The company has a market cap of $55.03 million, a price-to-earnings ratio of -3.89 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.20. On average, analysts anticipate that MiNK Therapeutics, Inc. will post -2.75 EPS for the current year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC bought a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent SEC filing. 2.87% of the stock is owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.